SCHEMBL683615

SCHEMBL683615

Cn1c(=O)c2c(ncn2CN2CCC(c3ccccc3)CC2)n(C)c1=O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2B P29275 7/20 0.57
SMN1; SMN2 Q16637 2/20 0.57
RXFP1 Q9HBX9 2/20 0.57
ALDH1A1 P00352 1/20 0.56
TSHR P16473 1/20 0.54
HTR7 P34969 1/20 0.53
HTR6 P50406 1/20 0.53
CHRM2 P08172 1/20 0.52
HTR1A P08908 1/20 0.52
CHRM1 P11229 1/20 0.52
DRD2 P14416 1/20 0.52
ADRA1D P25100 1/20 0.52
ADRA1A P35348 1/20 0.52
ADRA1B P35368 1/20 0.52
KMT2A Q03164 1/20 0.52
CASP1 P29466 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
LMNA P02545 2/20 0.49
MAPT P10636 1/20 0.49
MAPK1 P28482 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7316541 0.91 ALDH1A1 (0.59) ADORA2BSMN1; SMN2RXFP1ALDH1A1TSHR
SCHEMBL7320319 0.89 HTR7 (0.68) ADORA2BSMN1; SMN2RXFP1ALDH1A1TSHR
SCHEMBL7313390 0.89 HTR1A (0.65) ADORA2BSMN1; SMN2RXFP1ALDH1A1TSHR
SCHEMBL684006 0.84 CHRM2 (0.72) ADORA2BSMN1; SMN2RXFP1ALDH1A1TSHR
SCHEMBL683671 0.82 HTR2A (0.54) ADORA2BSMN1; SMN2RXFP1TSHRKMT2A
SCHEMBL683655 0.82 HTR7 (0.77) ADORA2BSMN1; SMN2RXFP1ALDH1A1TSHR
SCHEMBL7742121 0.81 ADORA2B (0.62) ADORA2BSMN1; SMN2RXFP1ALDH1A1KMT2A
SCHEMBL7736301 0.80 ADORA2B (0.60) ADORA2BSMN1; SMN2RXFP1ALDH1A1KMT2A
SCHEMBL684364 0.79 HTR1A (0.66) ADORA2BSMN1; SMN2RXFP1ALDH1A1TSHR
SCHEMBL7306929 0.78 HTR7 (0.59) ADORA2BSMN1; SMN2RXFP1TSHRHTR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110269717-A1 NEUROGENESIS BY MODULATING ANGIOTENSIN BRAINCELLS INC. (US) 2011-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110269717-A1 NEUROGENESIS BY MODULATING ANGIOTENSIN NGF, DCX, BDNF ADORA2B 786/4885SMN1; SMN2 907/4885RXFP1 211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.